Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
10.0
5.5
Journals
Pharmaceutics
Special Issues
Application of Nanostructured Lipid Carriers in Antibacterial and Anticancer
share announcement

Application of Nanostructured Lipid Carriers in Antibacterial and Anticancer

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: closed (10 June 2025) | Viewed by 2896

Special Issue Editor

Dr. Lígia N.M. Ribeiro

E-Mail Website
Guest Editor
Institute of Biotechnology, Federal University of Uberlandia, Uberlandia 38408-100, MG, Brazil
Interests: nanocolloidal systems for bioactive sustained delivery; nanoformulation characterization; nanotoxicity and efficacy assays
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Nanostructured lipid carriers (NLC) represent a significant advancement in drug delivery systems, offering improved bioavailability, stability, and the targeted delivery of therapeutic agents. Pharmaceutics is proud to present a Special Issue focused on the innovative applications of NLC as antibacterial and anticancer treatment candidates. This issue aims to explore the potential of NLC in enhancing the efficacy, stability, and targeted delivery of therapeutic agents. The scope encompasses the design, development, and clinical evaluation of NLC-based formulations, highlighting their role in overcoming drug resistance and minimizing side effects in both antibacterial and anticancer treatments. By consolidating cutting-edge research and reviews, this Special Issue seeks to provide a comprehensive understanding of the mechanisms and benefits of NLC, fostering advancements in pharmaceutical sciences. We invite researchers and practitioners to contribute their original research articles or reviews to drive innovation and improve patient outcomes in antibacterial and anticancer therapies. 

Dr. Lígia N.M. Ribeiro
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanostructured lipid carriers
  • antibacterial therapy
  • anticancer therapy
  • drug delivery
  • pharmaceutical nanotechnology
  • targeted delivery
  • drug resistance
  • clinical evaluation

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

18 pages, 2967 KiB  
Article
Adenoviruses Encapsulated in PEGylated DOTAP-Folate Liposomes Are Protected from the Pre-Existing Humoral Immune Response
by Abraham T. Phung, Jaimin R. Shah, Tao Dong, Omonigho Aisagbonhi, William C. Trogler, Andrew C. Kummel and Sarah L. Blair
Pharmaceutics 2025, 17(6), 769; https://doi.org/10.3390/pharmaceutics17060769 - 11 Jun 2025
Viewed by 402
Abstract
Background/Objectives: While adenovirus (Ad) therapies have been proven to be effective in local administration, systemic Ad treatments have shown limited success due to pre-existing antibodies in the human blood that neutralize the virus. We developed a liposome coating procedure that protects the [...] Read more.
Background/Objectives: While adenovirus (Ad) therapies have been proven to be effective in local administration, systemic Ad treatments have shown limited success due to pre-existing antibodies in the human blood that neutralize the virus. We developed a liposome coating procedure that protects the Ad from pre-existing neutralizing antibodies in human blood. To assess the in vivo stability of the liposomes, the present study used a novel in vivo method to quantitatively assess the protective capabilities of liposome-encapsulated Ad (DfAd) from neutralizing antibodies. Methods: The assay systemically administers DfAd with a green fluorescent protein transgene (DfAd-GFP) into pre-immunized mice and allows it to circulate in the presence of neutralizing antibodies; the infected blood is extracted and used to transduce HEK293 cells, which emits fluorescence in the presence of protected, un-neutralized Ad. Results: The PEGylated liposome formulation provides 12× protection in vivo relative to unencapsulated Ads. In vitro optimization of the liposome coating reveals a strong correlation between the structural stability of liposomes and protection against anti-Ad neutralizing antibodies, where DSPE-PEG2000-carboxylic acid (DSPE-PEG2000-CA) is a critical component for liposome stability and increasing protection against antibody neutralization of the encapsulated Ad. Conclusions: The findings in the present study confirm that the DfAd liposome can protect against neutralizing antibodies in blood circulation. The novel in vivo assay for liposome protection against neutralizing antibodies and in vitro experiments in the present study provide new tools and insights toward designing liposome–Ad complexes for the systemic treatment of cancer. Full article
(This article belongs to the Special Issue Application of Nanostructured Lipid Carriers in Antibacterial and Anticancer)
►▼ Show Figures

Figure 1

14 pages, 2422 KiB  
Article
Antimicrobial Activity of Essential-Oil-Based Nanostructured Lipid Carriers against Campylobacter Spp. Isolated from Chicken Carcasses
by Henrique Machado Pires, Luciana Machado Bastos, Elenice Francisco da Silva, Belchiolina Beatriz Fonseca, Simone Sommerfeld, Robson José de Oliveira Junior and Lígia Nunes de Morais Ribeiro
Pharmaceutics 2024, 16(7), 922; https://doi.org/10.3390/pharmaceutics16070922 - 11 Jul 2024
Cited by 4 | Viewed by 1892
Abstract
Campylobacter is a virulent Gram-negative bacterial genus mainly found in the intestines of poultry. The indiscriminate use of traditional antibiotics has led to drug resistance in these pathogens, necessitating the development of more efficient and less toxic therapies. Despite their complex biologically active [...] Read more.
Campylobacter is a virulent Gram-negative bacterial genus mainly found in the intestines of poultry. The indiscriminate use of traditional antibiotics has led to drug resistance in these pathogens, necessitating the development of more efficient and less toxic therapies. Despite their complex biologically active structures, the clinical applications of essential oils (EOs) remain limited. Therefore, this study aimed to increase the bioavailability, stability, and biocompatibility and decrease the photodegradation and toxicity of EO using nanotechnology. The diffusion disk test revealed the potent anti-Campylobacter activity of cinnamon, lemongrass, clove, geranium, and oregano EOs (>50 mm). These were subsequently used to prepare nanostructured lipid carriers (NLCs). Formulations containing these EOs inhibited Campylobacter spp. growth at low concentrations (0.2 mg/mL). The particle size, polydispersity index, and zeta potential of these systems were monitored, confirming its physicochemical stability for 210 days at 25 °C. FTIR-ATR and DSC analyses confirmed excellent miscibility among the excipients, and FE-SEM elucidated a spherical shape with well-delimited contours of nanoparticles. The best NLCs were tested regarding nanotoxicity in a chicken embryo model. These results indicate that the NLC-based geranium EO is the most promising and safe system for the control and treatment of multidrug-resistant strains of Campylobacter spp. Full article
(This article belongs to the Special Issue Application of Nanostructured Lipid Carriers in Antibacterial and Anticancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop